[CAS NO. 51-77-4] Gefarnate
PRODUCTS SPECIFICATIONS [51-77-4]
DESCRIPTION [51-77-4]
Overview
| MDL | MFCD00129086 |
|---|---|
| Molecular Weight | 400.64 |
| Molecular Formula | C27H44O2 |
| SMILES | C/C(C)=C\CC/C(C)=C/CC/C(C)=C/CCC(OC/C=C(C)/CC/C=C(C)/C)=O |
Summary
Gefarnate is a drug used for the treatment of gastritis and gastric ulcer, and has been proposed for use in the treatment of dry eye syndrome.
In Vitro
Gefarnate (0.001, 0.01, or 0.1 mg/mL) increases mucin-like glycoprotein secretion in a dose-dependent fashion, but the difference from the control is significant only at the concentration of 0.1 mg/mL. Gefarnate specifically stimulates the mucin-like glycoprotein secretion [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT01051388 | Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan|Gastro-Intestinal Medical Care Research Center |
Cardio-cerebrovascular Disease
|
August 2008 | Phase 3 |
| NCT03610321 | First Affiliated Hospital of Harbin Medical University |
Coronary Artery Disease
|
September 1, 2019 | Phase 2|Phase 3 |
| NCT00762359 | Takeda |
Stomach Ulcer|Duodenal Ulcer
|
May 2007 | Phase 3 |
| NCT00787254 | Takeda |
Stomach Ulcer|Duodenal Ulcer
|
April 2007 | Phase 3 |
Appearance
Liquid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Pure form | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 31.25 mg/mL ( 78.00 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.4960 mL | 12.4800 mL | 24.9601 mL |
| 5 mM | 0.4992 mL | 2.4960 mL | 4.9920 mL |
| 10 mM | 0.2496 mL | 1.2480 mL | 2.4960 mL |
Synonyms